Marsh McLennan (MRSH) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is modestly constructive — consensus is a manageable bar, peer commentary confirms mid-single-digit organic growth is tracking, and the Greensill litigation charge is a Q1 one-time item that clears the deck; the biggest swing factor is whether Marsh organic growth can sustain the 4% underlying pace seen in Q1 or re-accelerate toward the 5%+ level peers are guiding.

Heading into the Q2 2026 print, the bar for MRSH looks achievable but not easy. Consensus expects total revenue of approximately $7.28 billion and adjusted EPS of $2.89, implying roughly 4% revenue growth and a ~29% adjusted operating margin — both broadly in line with Q1 2026 actuals and management’s Thrive program trajectory. Guidance/tone has been stable since the April 16 Q1 call: CEO John Doyle described a “solid start to the year” in a “dynamic and challenging environment,” and no post-earnings guidance revision has been issued. Estimate revisions have drifted modestly lower since last earnings — Q2 adjusted EPS consensus has slipped from ~$2.91 to ~$2.89 — suggesting the street has trimmed rather than built in upside, which creates a small cushion. The stock has recovered from a post-Q1 trough near $159 to ~$182, essentially flat since last earnings, meaning the market has not pre-priced a meaningful beat; at ~16.8x NTM P/E the multiple is below its 12-month average, offering room for re-rating if results impress. The key wildcard is FX headwinds: with roughly half of revenue generated internationally, a stronger dollar could shave 1–2 points off reported growth even if underlying trends are solid, and the Greensill litigation charge ($425M in Q1) has reset investor attention to litigation risk as an ongoing overhang.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on revenue and EPS, with the adjusted operating margin the tighter call; Marsh organic growth rate is the bigger swing factor — a re-acceleration toward 5% would be the clearest positive catalyst, while a miss on margin would be the most punishing outcome.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha consensus and actuals data. Q1 2026 actuals from MRSH Q1 2026 earnings release (April 16, 2026). Q2 2026 consensus as of July 20, 2026. Note: MRSH does not provide specific quarterly revenue or EPS guidance; the “Guidance” column reflects the absence of formal quarterly guidance rather than a miss vs. a stated range.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance posture is unchanged since the Q1 2026 earnings call — no post-earnings revisions have been issued. Management’s tone remains constructive but measured, with the Thrive program as the multi-year margin driver and FX/litigation as the key risks to watch.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have drifted modestly lower since the Q1 earnings print — Q2 adjusted EPS is down ~$0.02 and FY 2026 EPS is essentially flat — suggesting the street has trimmed rather than built in upside. The gap between current consensus and the post-Q1 baseline is small, creating a low-risk cushion rather than a meaningful divergence.

Note: MRSH does not issue formal quarterly or annual EPS/revenue guidance. The “Initial Guidance” and “Current Guidance” columns reflect the absence of formal guidance. Estimate baselines use the May 1, 2026 as-of date from Visible Alpha (closest available post-Q1 snapshot). Source: Visible Alpha consensus and actuals data.

5. Stock Performance

Key Takeaway: MRSH has lagged both KIE and the S&P 500 since Q1 earnings, driven primarily by multiple compression (NTM P/E down ~13.5% over 6 months) rather than earnings deterioration — the stock’s recent recovery from ~$159 to ~$182 has been multiple-led, suggesting sentiment is improving but the re-rating is not yet complete.

Since the Q1 2026 earnings date (April 16, 2026), MRSH opened at $182.57 and closed at $182.10 on July 21, 2026 — essentially flat (+0.0% indexed). Over the same period, KIE (SPDR S&P Insurance ETF) gained approximately +11.2% and the S&P 500 (SPY) gained approximately +5.8%. MRSH significantly underperformed both benchmarks, with the gap most pronounced in May when the stock fell to a trough near $159 (approximately -13% from the earnings date). The recovery from the May trough was driven by improving sentiment around the insurance brokerage sector (KIE also rallied strongly) and a broader market recovery. The stock’s underperformance vs. KIE reflects MRSH-specific headwinds: the $425M Greensill litigation charge in Q1 weighed on sentiment, and the stock’s NTM P/E multiple compressed from ~19.5x (6 months ago) to ~16.8x currently — a ~13.5% de-rating. The 12-month price performance of -13.7% is almost entirely explained by multiple contraction (-26.6% on P/E), partially offset by earnings growth.

Current NTM multiples: P/E 16.8x | EV/EBITDA 13.4x | P/FCF 17.5x | EV/Sales 3.7x. Source: Stock performance decomposition data (snapshot July 20, 2026).

Indexed Performance Since Q1 2026 Earnings (April 16, 2026 = 100):

Source: Yahoo Finance stock price data. KIE = SPDR S&P Insurance ETF (appropriate benchmark for MRSH’s insurance brokerage and risk services sub-sector). SPY = SPDR S&P 500 ETF.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the $425M Greensill litigation charge taken in Q1, which reset investor attention to legal risk; beyond that, the sector backdrop is constructive with peers reporting strong Q2 results and the Thrive program on track.

• Apr 16, 2026 — Q1 2026 Earnings: $425M Greensill Litigation Charge. MRSH reported Q1 revenue of $7.6B (+8% reported, +4% underlying) and adjusted EPS of $3.29 (+8%), but GAAP operating income fell 12% due to a $425M charge related to the Greensill litigation. Implication: Clears the deck for Q2 but flags ongoing litigation risk; investors will watch for any further disclosures on the call.
• Apr 16, 2026 — Thrive Program Update. CEO John Doyle confirmed the three-year Thrive program (launched Q3 2025) is on track, focused on accelerating growth and improving efficiency. Implication: Margin expansion story remains intact; Q2 adjusted margin of ~29% would be consistent with the program’s trajectory.
• Apr 16, 2026 — Capital Return: $750M Buyback in Q1. MRSH repurchased ~4.2M shares for $750M in Q1 and issued/repaid $600M of senior notes. Implication: Signals management confidence in the balance sheet; pace of buybacks in Q2 will be a watch item.
• May 21, 2026 — Annual Meeting: Board Re-Elected. All directors were re-elected at the 2026 Annual Meeting. No material governance changes. Implication: Neutral; no leadership disruption heading into Q2.
• Jun 23, 2026 — Q2 Earnings Call Scheduled for July 21. MRSH confirmed Q2 results will be released before market open on July 21, 2026, with a call at 8:30 a.m. EDT led by CEO John Doyle and COO/CFO Mark McGivney. Implication: No pre-announcement or guidance update was issued alongside this notice, consistent with stable trading.
• Jul 17, 2026 — Peer TRV Reports Strong Q2. Travelers (TRV) reported Q2 2026 results with a favorable combined ratio (~150bps better than expected) and higher investment income. Implication: Positive read-through for the insurance sector broadly; supports a constructive backdrop for MRSH’s Risk & Insurance Services segment.
• Jul 14–17, 2026 — Broad Financial Sector Earnings Beat Cycle. Major banks (JPM, BAC, GS, MS, C, WFC) and insurers (WRB, TRV) all reported strong Q2 results, with equity trading, investment banking, and fee income broadly beating consensus. Implication: Positive macro backdrop for MRSH’s consulting and risk advisory businesses; strong capital markets activity supports demand for risk management services.
• Jun 26, 2026 — AON Authorizes $7.5B Additional Share Repurchase. Aon’s board approved a new $7.5B buyback authorization (total ~$8.3B including remaining prior authorization). Implication: Signals AON’s preference for capital return over large M&A; could reduce competitive pressure on MRSH for acquisition targets.
• Jun 5, 2026 — Brown & Brown Expands Credit Facility to $1.75B. BRO increased its revolving credit from $800M to $1.25B and added $500M in new term loans. Implication: Signals BRO is positioning for M&A; could increase competition for mid-market brokerage acquisition targets.
• Jun 17, 2026 — AJG Pre-Q2 Investor Meeting: Confirms ~5% Q2 Organic Growth. Arthur J. Gallagher confirmed mid-single-digit organic growth tracking for Q2 2026 across its brokerage segment, with casualty pricing firm and property pricing easing. Implication: Strong positive read-through for MRSH’s Marsh segment organic growth; see Peer Commentary section for full detail.

7. Insider Transaction Activity

Key Takeaway: No open-market insider transactions (Form 4 buys or sells) were identified for MRSH in the period since Q1 2026 earnings. The absence of notable insider selling is a mild positive signal; the absence of open-market buying is neutral given the stock’s recent underperformance.

No open-market insider buys or sells (Form 4, transaction codes P/S) were found for MRSH in the period from April 16, 2026 through July 20, 2026. No Form 144 notices of intended sale were identified for MRSH in this period. The data search covered SEC EDGAR filings and the insider transaction dataset for the relevant window.

Note on peer insider activity: AON General Counsel Darren Zeidel filed a Form 144 notice of intended sale ($216K, July 7, 2026) and executed a planned 10b5-1 sale ($216K, July 7, 2026). This is a routine planned sale and not a directional signal for MRSH.

8. Peer Commentary & Current-Quarter Read-Through

Key Takeaway: AJG’s June 17 pre-Q2 investor meeting is the most actionable read-through: two months into Q2, the brokerage market is tracking mid-single-digit organic growth, casualty pricing is firm, property pricing is easing but not collapsing, and underlying business activity is positive. This is a net positive for MRSH’s Marsh and Guy Carpenter segments heading into the print.

Filter applied: Only commentary made during Q2 2026 (after April 1, 2026) or after peers’ Q1 2026 earnings that addresses current-quarter conditions is included below. Descriptions of prior-quarter (Q1 2026) results are excluded. Items that are indirect (capital allocation, M&A positioning) are labeled separately.

A. Arthur J. Gallagher (AJG) — Pre-Q2 2026 Investor Meeting, June 17, 2026

Source: AJG Pre-Q2 Investor Meeting with Management transcript, June 17, 2026. This is the highest-quality current-quarter read-through available — AJG management provided explicit Q2 2026 organic growth guidance and detailed market commentary two months into the quarter.

Organic Growth — Q2 2026 Tracking

• AJG brokerage segment Q2 2026 organic growth: ~5%. CFO Doug Hall stated: “Now being two months into the second quarter, I have further confidence in the second quarter organic of about 5%.” Full-year brokerage organic guidance is ~5.5%.
• Read-through for MRSH (Positive): Consensus expects Marsh organic growth of ~3.6% for Q2 2026 — below AJG’s 5% pace. AJG’s confidence in mid-single-digit growth, driven by a diversified set of factors beyond pricing, suggests the market environment is supportive enough for MRSH to meet or modestly exceed its ~3.6% consensus. A re-acceleration toward 4–5% would be a positive surprise.
• AJG Risk Management (Gallagher Bassett) Q2 organic: ~11%. Driven by large new business wins and international growth. Full-year guidance raised to ~8%.
• Read-through for MRSH (Positive): Guy Carpenter (MRSH’s reinsurance segment) consensus organic growth is ~3.6% for Q2. AJG’s strong risk management growth signals healthy demand for risk advisory services, though Guy Carpenter’s reinsurance focus means it is more exposed to pricing dynamics than claims management.
• AJG Benefits (GBS) Q2 organic: ~3%. “Second quarter organic growth of approximately 3% and full 2026 organic growth of 4% are tracking in line with our expectations.”
• Read-through for MRSH Mercer (Positive): Consensus expects Mercer organic growth of ~4.1% for Q2 2026. AJG’s 3% benefits organic is slightly below Mercer’s consensus, but the direction is consistent. Rising medical costs (high single-digit to ~10% premium increases in fully insured; mid-teens in stop-loss) are a tailwind for Mercer Health.
• Underlying business activity through mid-June: positive. AJG CEO Pat Gallagher: “Through mid-June, our daily revenue indications from audits, endorsements and cancellations are still in positive territory and continue to point to solid underlying business activity for our clients in the US.” Net new business spread remains positive; no meaningful impact from mid-term policy cancellations.
• Read-through for MRSH (Positive): Positive underlying business activity through mid-June is a strong signal that Q2 organic growth for MRSH is tracking at or above the consensus estimate.

Insurance Pricing — Q2 2026 (First Two Months)

• Property pricing: down ~9% overall (U.S. retail: -11%; Canada: -8%; UK: -2%; Australia: -3%; New Zealand: -10%). Larger accounts seeing more downward pressure; middle market steadier. AJG CFO: “Property will continue to move lower somewhat throughout the year” but does not expect another ~10% step-down in 2027.
• Read-through for MRSH (Negative for property lines): Continued property rate softening is a headwind for Marsh’s property-exposed book, particularly for large commercial accounts. However, MRSH’s diversified mix (casualty, specialty, reinsurance, consulting) limits the impact.
• Casualty pricing: up ~5% overall (U.S. retail: +7%, including GL +4%, commercial auto +8%, umbrella +8%). “Casualty remains firmer given ongoing pressure on lost costs and underwriting margins.” Casualty increases are more uniform across account sizes than property.
• Read-through for MRSH (Positive for casualty lines): Firm casualty pricing supports Marsh’s casualty book and is a tailwind for organic growth. Commercial auto acceleration (driven by claims severity) is a market-wide trend benefiting all large brokers.
• D&O, cyber, and professional lines: up ~2%. Workers’ compensation: flat. Personal lines: +3%. Cyber: +5% in U.S. retail.
• Read-through for MRSH (Mixed): Modest increases in specialty lines are a mild positive. Flat workers’ comp is neutral. Cyber growth (+5%) is a positive for MRSH’s specialty and cyber advisory practices.
• Reinsurance market (AJG Re / Tom Gallagher): abundant capacity, meaningful risk-adjusted rate reductions in property and specialty, broadly stable casualty. 7/1 renewals backdrop: “ample capacity, continued competition in many lines.” Middle East conflict has not changed overall reinsurance market dynamics.
• Read-through for MRSH Guy Carpenter (Mixed): Property reinsurance rate reductions are a headwind for Guy Carpenter’s revenue growth, but stable casualty and strong advisory demand partially offset. AJG Re’s view that “growth is not dependent upon rates” applies equally to Guy Carpenter’s advisory-driven model.
• Health/benefits pricing: high single-digit to ~10% premium increases in fully insured; mid-teens to above 20% in stop-loss. Driven by increased utilization, provider consolidation, and GLP-1 drug costs.
• Read-through for MRSH Mercer Health (Positive): Rising medical costs and premium increases are a strong tailwind for Mercer’s Health segment, which advises employers on benefits design and cost management. This supports Mercer’s ~4% organic growth consensus.

New Business, Retention & AI

• Net new business spread: positive. AJG’s close ratio improves from ~30% to 40–50% when using data/analytics tools (Gallagher Drive). Pipelines described as “very healthy” across all segments.
• Read-through for MRSH (Positive): A positive net new business environment benefits all large brokers. MRSH’s scale, data assets, and Oliver Wyman consulting capabilities are analogous competitive advantages.
• AI integration: AJG is deploying AI across brokerage (quote analysis, loss data summarization), claims (severity prediction, litigation prevention), and reinsurance (data extraction, analytics). CFO estimates potential cost savings of 5% in producer/sales layer, 10–15% in service layer, and 20–30% in back office over the next few years.
• Read-through for MRSH (Positive): AJG’s AI deployment roadmap and margin expansion potential are directly applicable to MRSH’s Thrive program, which similarly targets efficiency gains. If MRSH can demonstrate comparable AI-driven productivity improvements, it supports the margin expansion narrative.
• Data center insurance: AJG reported a “very large win just last week” in the data center market, describing it as “part of a broader complex risk opportunity.”
• Read-through for MRSH (Positive): Data center and AI infrastructure insurance is a growing specialty niche. MRSH’s Marsh segment, with its large commercial and specialty capabilities, is well-positioned to compete for these complex placements.

B. Aon (AON) — 8-K Filed July 1, 2026 (Indirect / Capital Allocation Read-Through Only)

Note: The AON 8-K filed July 1, 2026 does not contain commentary on current-quarter trading, insurance pricing, new business, or margins. The items below are indirect capital-allocation signals only.

• Jun 26, 2026 — AON Board Authorizes $7.5B Additional Share Repurchase. Total authorized repurchase capacity rises to ~$8.3B (including ~$0.8B remaining from prior program as of March 31, 2026).
• Indirect read-through for MRSH (Mildly Positive): AON’s large buyback authorization signals a preference for capital return over large-scale M&A in the near term. This reduces the likelihood of AON competing aggressively for major acquisition targets, potentially easing competitive pressure on MRSH in the M&A market.
• Jun 26, 2026 — AON CEO Greg Case Employment Extended to June 30, 2027. Amendment to international assignment letter extends Case’s term by one year.
• Indirect read-through for MRSH (Neutral): Leadership continuity at AON is neutral for MRSH; no strategic pivot implied.
• Jun 26, 2026 — AON Annual Meeting: Executive Compensation Vote Failed. The advisory say-on-pay resolution was not approved (69.9M For vs. 110.8M Against).
• Indirect read-through for MRSH (Neutral): Shareholder governance pressure at AON is an AON-specific issue; no direct read-through for MRSH’s operations or results.

C. Brown & Brown (BRO) — 8-K Filed June 5, 2026 (Indirect / M&A Positioning Only)

Note: The BRO 8-K filed June 5, 2026 relates solely to a credit facility amendment and does not contain commentary on current-quarter trading, pricing, new business, or margins. The item below is an indirect M&A positioning signal only.

• Jun 5, 2026 — BRO Expands Credit Facility: Revolving Credit $800M → $1.25B; New Term Loans of $500M. Total facility capacity rises to ~$1.75B. As of filing, $825M outstanding. Maturities extended to June 2029–2031.
• Indirect read-through for MRSH (Mildly Negative): BRO’s significant credit facility expansion signals it is positioning for M&A in the fragmented insurance brokerage market. This could increase competition for mid-market acquisition targets that MRSH’s Marsh segment might also pursue. However, BRO operates primarily in the middle market, while MRSH’s M&A focus tends toward larger, more complex businesses.

D. Summary Read-Through Scorecard